Novartis is thinking about the future of medicine to improve people's quality of life and extend their life span. As a world-renowned medical and health enterprise, we use innovative science and digital technology to create transformative treatments in the field of medical and health demand growth. In the process of exploring new drugs, we continue to innovate and invest in research and development at the forefront of the industry. Globally, more than 750 million patients benefit from novartis products, and we continue to explore more innovative ways to make our innovative therapies benefit more patients. Novartis employs about 105,000 people in more than 140 countries. Novartis' operations in China date back more than 200 years. As early as 1886, jia ji company began to promote dyes in China, after which ciba company and sandex company also successively entered the Chinese market. In 1970, jiaji company and ciba company merged; In 1987, Beijing ciba - jiagi pharmaceutical co., ltd. was established in China, which was the predecessor of Beijing novartis pharmaceutical co., LTD. In 1996, ciba-jiaji and sandoz merged to form novartis. Novartis' business in China includes novartis oncology, novartis pharmaceuticals and sandoz. It has three major production bases in China, and set up research and development facilities in Beijing, Shanghai and jiangsu. From research and development to production and sales, novartis provides comprehensive services to the health of the Chinese people with a diversified business portfolio. Currently, novartis has more than 9,100 employees in China.